Buparlisib (BKM120)

Name: Buparlisib (BKM120)
Brand: Selleck Chemicals
SKU: S2247
Rating: 5 (194 reviews)

For research use only.

Catalog No.S2247 Synonyms: NVP-BKM120

194 publications

CAS No. 944396-07-0

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.

Selleck's Buparlisib (BKM120) has been cited by 194 publications

Cell, 2020, 25;181(7):1596-1611.e27.

PubMed: 32559461 ( click the link to review the publication )

Cell, 2020, S0092-8674(20)31394-5

PubMed: 33147445 ( click the link to review the publication )

Cancer Cell, 2020, 37(2):183-199

PubMed: 31978326 ( click the link to review the publication )

Nat Immunol, 2020, 21(4):442-454

PubMed: 32152508 ( click the link to review the publication )

Science, 2019, 364(6441)

PubMed: 31097636 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):922-938

PubMed: 30537514 ( click the link to review the publication )

Cancer Cell, 2018, 33(1):91-107

PubMed: 29316436 ( click the link to review the publication )

Cell, 2017, 161(4):803-16

PubMed: 25913192 ( click the link to review the publication )

Cancer Discov, 2017, 7(9):1018-1029

PubMed: 28619981 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):232-45

PubMed: 24356096 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):186-99

PubMed: 24302555 ( click the link to review the publication )

Cell, 2012, 27;149(3):656-70.

PubMed: 22541435 ( click the link to review the publication )

Nat Med, 2012, 18(6):892-901

PubMed: 22610277 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):108

PubMed: 33479203 ( click the link to review the publication )

Cancer Cell Int, 2021, 21(1):24

PubMed: 33407478 ( click the link to review the publication )

Cell Biol Int, 2021, 10.1002/cbin.11557

PubMed: 33501756 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 33(1):108221

PubMed: 33027668 ( click the link to review the publication )
Sci Signal, 2020, 3;13(621) pii: eaax2364

PubMed: 32127496 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2500

PubMed: 32899250 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01074-2

PubMed: 32963347 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(11):3765-3783

PubMed: 33294266 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(12):4488-4497

PubMed: 33415013 ( click the link to review the publication )

Mol Cancer Res, 2020, 11

PubMed: 32161139 ( click the link to review the publication )

Sci Rep, 2020, 10(1):16208

PubMed: 33004905 ( click the link to review the publication )

Front Neurosci, 2020, 2;14:223

PubMed: 32300287 ( click the link to review the publication )

Eur J Pharmacol, 2020, 870:172821

PubMed: 31770526 ( click the link to review the publication )

Cell Biol Int, 2020, 10.1002/cbin.11322

PubMed: 32068318 ( click the link to review the publication )

Turk J Haematol, 2020, 37(3):167-176

PubMed: 32160736 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):724

PubMed: 32758183 ( click the link to review the publication )

FASEB Bioadv, 2020, 2(2):126-144

PubMed: 32123862 ( click the link to review the publication )

Commun Biol, 2020, 3(1):593

PubMed: 33087841 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12673

PubMed: 32191822 ( click the link to review the publication )

Cancer, 2020, 10.1002/cncr.33071

PubMed: 32767682 ( click the link to review the publication )

Small GTPases, 2020, 10.1080/21541248

PubMed: 32043900 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(2):226-237

PubMed: 30692625 ( click the link to review the publication )

Nat Commun, 2019, 10(1):259

PubMed: 30651547 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2910

PubMed: 31266951 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(6):1061-1076

PubMed: 30825612 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0556-z

PubMed: 31462739 ( click the link to review the publication )
Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Theranostics, 2019, 9(8):2380-2394

PubMed: 31149050 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0422-6

PubMed: 31570855 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E37

PubMed: 30609754 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Mol Ther Oncolytics, 2019, 13:58-66

PubMed: 31016228 ( click the link to review the publication )

Cancer Discov, 2019, 9(9):1306-1323

PubMed: 31217297 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):834-844

PubMed: 30787173 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(18):7780-7795

PubMed: 31545294 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(12):2774-2788

PubMed: 31911861 ( click the link to review the publication )

J Cell Physiol, 2019, 234(7):10907-10917

PubMed: 30536897 ( click the link to review the publication )

Front Oncol, 2019, 0.87569444444

PubMed: 31428587 ( click the link to review the publication )

Front Oncol, 2019, 9:1119

PubMed: 31750239 ( click the link to review the publication )

Eur J Immunol, 2019, doi: 101002/eji201948241

PubMed: 31621069 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Biochem J, 2019, 476(23):3583-3593

PubMed: 31738383 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

Chem Biol Interact, 2019, 302:101-107

PubMed: 30703376 ( click the link to review the publication )

Eur J Pharmacol, 2019, 842:89-98

PubMed: 30401630 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(3):546-552

PubMed: 30981504 ( click the link to review the publication )
Leuk Lymphoma, 2019, 10.1080/10428194.2019.1594211

PubMed: 30947576 ( click the link to review the publication )

Int J Hematol, 2019, 110(2):213-227

PubMed: 31129802 ( click the link to review the publication )

Oncol Lett, 2019, 17(3-:3151-3162

PubMed: 30867745 ( click the link to review the publication )

Oncol Lett, 2019, 18(6):6249-6260

PubMed: 31788102 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 05:31

PubMed: 31552290 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4550

PubMed: 30382095 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1357

PubMed: 29636477 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(5)

PubMed: 29650805 ( click the link to review the publication )

Cancer Res, 2018, 78(8):2000-2013

PubMed: 29437705 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Cancer Res, 2018, 78(14):4007-4021

PubMed: 29760046 ( click the link to review the publication )

Cell Rep, 2018, 24(8):2155-2166

PubMed: 30134175 ( click the link to review the publication )

Cell Rep, 2018, 24(2):463-478

PubMed: 29996106 ( click the link to review the publication )

Elife, 2018, 7e33718

PubMed: 30475204 ( click the link to review the publication )

Int J Cancer, 2018, 143(5):1188-1201

PubMed: 29582409 ( click the link to review the publication )

Int J Cancer, 2018, 142(9):1926-1937

PubMed: 29210065 ( click the link to review the publication )

Oncogene, 2018, 37(3):363-376

PubMed: 28945225 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

Sci Signal, 2018,

PubMed: 29535262 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )
Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Oncol Rep, 2018, 40(6):3223-3234

PubMed: 30272286 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):479-487

PubMed: 29767248 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):3321-3328

PubMed: 29435074 ( click the link to review the publication )

NPJ Breast Cancer, 2018, 4:36

PubMed: 30456298 ( click the link to review the publication )

Oncotarget, 2018, 9(56):30869-30882

PubMed: 30112114 ( click the link to review the publication )

J Exp Med, 2018, 215(1):159-175

PubMed: 29141866 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8:15021

PubMed: 28443643 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Dev Cell, 2017, 43(6):673-688

PubMed: 29103956 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(41):E8628-E8636

PubMed: 28973876 ( click the link to review the publication )

Cancer Res, 2017, 77(16):4448-4459

PubMed: 28652248 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

Mol Cell Proteomics, 2017, 16(10):1864-1888

PubMed: 28794006 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

SLAS Discov, 2017, 22(8):974-984

PubMed: 28644734 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28977994 ( click the link to review the publication )
Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52474-52487

PubMed: 28881745 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(13):21806-21817

PubMed: 28423521 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(44):76935-76948

PubMed: 29100359 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(12):1324-1335

PubMed: 27870828 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(3):644-56.

PubMed: 26224873 ( click the link to review the publication )

PLoS Biol, 2016, 14(11):e1002581

PubMed: 27880766 ( click the link to review the publication )

Cancer Res, 2016, 76(24):7168-7180

PubMed: 27913436 ( click the link to review the publication )

Cell Rep, 2016,

PubMed: 27292631 ( click the link to review the publication )

J Hematol Oncol, 2016, 9(1):113

PubMed: 27765055 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

J Transl Med, 2016, 14:56

PubMed: 26912358 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:308-317

PubMed: 27599915 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0147682

PubMed: 26821351 ( click the link to review the publication )

PLoS One, 2016, 10.1371/journal

PubMed: 27055253 ( click the link to review the publication )

Oncotarget, 2016, 7(41):67277-67287

PubMed: 27572309 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )
Sci Rep, 2016, 6:20189

PubMed: 26846842 ( click the link to review the publication )

Oncotarget, 2016, 7(45):72608-72621

PubMed: 27579615 ( click the link to review the publication )

J Clin Invest, 2015, 10.1172/JCI78018

PubMed: 25798617 ( click the link to review the publication )

J Clin Invest, 2015, 125(12):4559-71

PubMed: 26529251 ( click the link to review the publication )

Genes Dev, 2015, 29(16):1677-82

PubMed: 26272820 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2851-62

PubMed: 25977330 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.173

PubMed: 25982275 ( click the link to review the publication )

Glia, 2015, 63(10):1850-9

PubMed: 25944104 ( click the link to review the publication )

Cancer Discov, 2015, 5(11):1194-209

PubMed: 26293922 ( click the link to review the publication )

Gynecol Oncol, 2015, 138(1):165-73

PubMed: 25933683 ( click the link to review the publication )

Biomed Pharmacother, 2015, 75:40-50

PubMed: 26463630 ( click the link to review the publication )

Acta Pharmacol Sin, 2015, 10.1038/aps.2015.4

PubMed: 25864651 ( click the link to review the publication )

Cell Signal, 2015, 27(12):2389-400

PubMed: 26363466 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: ( click the link to review the publication )

Int J Biochem Cell Biol, 2015, 60C:34-42

PubMed: 25578563 ( click the link to review the publication )

Int Immunopharmacol, 2015, 28(1):675-85

PubMed: 26256696 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Immunol Res, 2015, 10.1007/s12026-015-8648-y

PubMed: 25869396 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015,

PubMed: 26253360 ( click the link to review the publication )

J Clin Invest, 2014, 124(12):5490-502

PubMed: 25401474 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )
J Exp Med, 2014, 211(13):2497-2505

PubMed: 25488980 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Rep, 2014, 8(5):1265-70

PubMed: 25176649 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

PLoS Pathog, 2014, 10(6):e1004196

PubMed: 24945378 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(1):R9

PubMed: 24451154 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(10):1520-31

PubMed: 25103499 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108780

PubMed: 25360799 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101969

PubMed: 25003333 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5295-303

PubMed: 24979463 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(21):5940-51

PubMed: 23918606 ( click the link to review the publication )

Cancer Res, 2013, 73(17):5459-72

PubMed: 23796563 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.509

PubMed: 24292683 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R55

PubMed: 23844554 ( click the link to review the publication )

Cell Commun Signal, 2013, 11(1):3

PubMed: 23311350 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

BMC Cancer, 2013, 13:465

PubMed: 24103747 ( click the link to review the publication )
Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

University Gattingen, 2013, Elisabeth Hand

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	Vps34 ^[1] (Cell-free assay)	View More
52 nM	116 nM	166 nM	262 nM	2.4 μM	View More

In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. ^[1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. ^[2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. ^[3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
glioma cell lines	NV\JVYJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUnBZnp3PzKq		M4TyZWlEPTB;MT2y{txO	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB4NUC4NEc,OjJyNkWwPFA9N2F-
U87	NFnBeXFCeG:ydH;zbZMhSXO\|YYm=	M1j4[\|LPxE1?	MUe3Nog>		NULEbZFEcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDhcoQh[2ynYY\l[EBRSVKSIHHu[EBk[XOyYYPlMVM>	MlHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyNkWwPFAoRjJ{ME[1NFgxRC:jPh?=
SNU-601	NELTNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXm3Nog>	MkLHSG1UVw>?	NH7wVGpKSzVyPUCuPFE3yrFyLkC2N:69VQ>?	NY\FSZY2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-1	M4PXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoGxO\|Jp	Mn;SSG1UVw>?	M{P2OmlEPTB;MT6wPFLDuTBwMEK4{txO	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF3OUixOEc,OjJzNUm4NVQ9N2F-
SNU-668	NUjidXpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVzFdpRlPzKq	NETJZ2xFVVOR	NH3lTXlKSzVyPUGuOVc6yrFyLkC3OO69VQ>?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF3OUixOEc,OjJzNUm4NVQ9N2F-
AGS	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF\oSY04Omh?	NHf6T4VFVVOR	NIXh[WVKSzVyPUGuO\|E1yrFyLkGxO:69VQ>?	NF;5eI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-216	NI\k[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXe3Nog>	M3XsUWROW09?	MXHJR\|UxRTJwNkmyxtExNjB6Mt88US=>	NHTuWpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-5	MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkXaO\|Jp	NYDVTXl2TE2VTx?=	M{fsdmlEPTB;MT6zOVHDuTBwMEmx{txO	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF3OUixOEc,OjJzNUm4NVQ9N2F-
SNU-638	M2nNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIC5PYc4Omh?	NYLXNI1wTE2VTx?=	MlzJTWM2OD1{LkK4NuKyOC5yNUROwG0>	NWn0fZQ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-16	M4DTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2LMUVczcA>?	NXHvVJpkTE2VTx?=	NHz5V4JKSzVyPUGuOVc{yrFyLkCwNe69VQ>?	NV\UXI9bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-484	MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVW3Nog>	NEf1TnRFVVOR	NY\kbXVmUUN3ME2xMlczQMLzMD6wOFXPxE1?	NEfmdVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-620	NFexfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGPrSGM4Omh?	NILEdldFVVOR	NULPeItGUUN3ME2yMlk{QcLzMD6wNFHPxE1?	M3LEUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
SNU-719	M2PSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{L6XFczcA>?	NXO3TIhMTE2VTx?=	M3q3R2lEPTB;Mz6wN\|fDuTBwMEOy{txO	M3TEZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
MM cell lines	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU[xNO69VQ>?	MXSyOIg>	NXTQfWlyTE2VTx?=	M3W5N2lEPTBidnHybYV{KGGvb37nJIRq\m[ncnXueEBk\WyuIHzpcoV{KGmwIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y5k\Q>?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJyN{S4OUc,OjJ{MEe0PFU9N2F-
ARP-1	NXHS[pc5SXCxcITvd4l{KEG\|c3H5	MnT0NVDPxE1?	Mk\WNlRp	MVnEUXNQ	MV;pcoR2[2W\|IF3NJINmdGxiYYDvdJRwe2m\|IITodo92\2hiY3HzdIF{\SCjY4TpeoF1cW:w	NIDYOJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKwO\|Q5PSd-MkKyNFc1QDV:L3G+
colon cancer cell lines	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2WxdVAuOTEQvF2=	MV[3Nog>	NFzTN4JFVVOR	MnnPTWM2OD1zzszN	NWrZPVBvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFM5PTdpPkKyOVQ{QDV5PD;hQi=>
gastric cancer cell lines	NYDnW2FXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHPNE0yOM7:TR?=	NX7aNGpIPzKq	NUC5dFR2TE2VTx?=	MoLITWM2OD1{LUZOwG0>	NF;FcmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0N\|g2Pyd-MkK1OFM5PTd:L3G+
HCT-116/HT-29/MKN-45	NGfOTVRCeG:ydH;zbZMhSXO\|YYm=	Mn\yNu69VQ>?	NY\zZXNYPDiq		Mn;Sd4hq\nRiaX6gS\|IheGijc3W=	MoiyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEO4OVcoRjJ{NUSzPFU4RC:jPh?=
HT-29 and HCT-116	NVnsOmFCS2G\|cHHz[UBie3OjeR?=	MUi1{txO	NWXrOGVvOjSq		NVPPdlY1cW6mdXPld{Bk[XOyYYPlJIFkfGm4aYT5	NVnHS4VTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFM5PTdpPkKyOVQ{QDV5PD;hQi=>
PIK3CA-mutant MCF7	NVr0TI5JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7GS2k2OD1zNkFCtVkydk4xvJzMSFUxRTl6MNMxNlc{dk1?	NGjVO3I4Omh?		M1;OeGdKPTB;MU[wxtE6OW6P78{MUGQ2OD17OEFCtVI4O26P	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ3M{m2O{c,OjJ4NUO5Olc9N2F-
PIK3CA-mutant MCF7	NUnkb5lOU2mwYYPlJGF{e2G7	NXz0WIMxUUN3ME2xNVTDuTOwTR?=	M3GzWlczcA>?		M3;pb2lEPTB;MUG0xtE{dk1iaX6gdoVlfWOrbnegRYt1KHCqb4PwbI9zgWyjdHnvckBt\X[nbIO=	MoDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4NUO5OlcoRjJ{NkWzPVY4RC:jPh?=
MCF7-myr-Akt	M{jnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\XXGdKPTB;Mkm5xtE3QG6P78{MUGQ2OO,:nkGwMFAxOG6P	MkTkO\|Jp		MUfHTVUxRTJ7OdMxOlhvVe,:jFzEOVDwxJ5zMDywNFBvVQ>?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ3M{m2O{c,OjJ4NUO5Olc9N2F-
Y1 cell line	NELMOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFS3VVgxNjIQvF2vNe69VQ>?	NGfpUWkzPGh?	MVfEUXNQ	M{TwNIlvcGmkaYTzJFYx97zHIHPlcIwhfmmjYnnsbZR6KGmwIF35Z{1U[3S{LYTyZY5{\mWldHXkJINmdGy\|	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ7MkmwOEc,OjJ4OUK5NFQ9N2F-
human NSCLC	MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\mV\|AvPS1{zszN	MVe3Nog>		MXXJR\|UxRTIQvF2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd6MUO5N{c,OjJ5OEGzPVM9N2F-
human NSCLC	MX7LbY5ie2ViQYPzZZk>	NETtblQy\|ryP	NUDESpc5OjSq		M2LCdolvcGmkaYTzJJRp\SCDa4SvcXRQWiC\|aXfuZYxqdmdicHH0bJdigSCjdDCzbEBi\nSncjD0doVifG2nboS=	M{TQVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ixN\|k{Lz5{Mke4NVM6OzxxYU6=
JVM2	NHXkRXpEgXSxdH;4bYNqfHliYYPzZZk>	M{LjSFAvOi1{MN88US=>	NVTrSXR3PzKq	Moe1SG1UVw>?	NIC1N\|hKSzVyPUCuPe69VQ>?	M{fhVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkO4OlM6Lz5{M{KzPFY{QTxxYU6=
EHEB	NXLFXGZHS3m2b4TvfIlkcXS7IHHzd4F6	NHnRdFAxNjJvMkFOwG0>	NHT4NGs4Omh?	MYnEUXNQ	NX\4Uo5RUUN3ME2wMlfPxE1?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ\|OE[zPUc,OjN{M{i2N\|k9N2F-
MEC2	MoHER5l1d3SxeHnjbZR6KGG\|c3H5	NXLKd\|Q5OC5{LUKw{txO	M4S0elczcA>?	M{nYXmROW09?	M4nyZWlEPTB;MD63{txO	NYrMTHl2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyN\|g3OzlpPkKzNlM5PjN7PD;hQi=>
primary B-CLL lymphocytes	MWPBdI9xfG:\|aYOgRZN{[Xl?	MnHITWM2OCCob4Kg[YFkcCCycnntZZJ6KGOnbHygcIlv\Q>?	NXT0N4FqOjSq	NHW0U2FFVVOR	MkDRTWM2OO,:nEROwG0h\m:{IHHscEBx[XSrZX70dy=>	NGPSUFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzPFY{QSd-MkOyN\|g3Ozl:L3G+
primary B-CLL lymphocytes	NGjnUVFMcW6jc3WgRZN{[Xl?	NFLFRXlKSzVyIH\vdkBm[WOqIIDybY1ienliY3XscEBtcW6n	NHXJUXYzPGh?		M4nCS4lvcGmkaYTzJJA4OFN4SzCmJFRGNUKSMTDlfJBz\XO\|aX;u	NHrmb3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzPFY{QSd-MkOyN\|g3Ozl:L3G+
SK-HEP1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkn5NU0zOM7:TR?=	NHrmbGE4Omh?	MmnCSG1UVw>?	M4GzemlEPTExvKyx{txO	Ml2wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2N{mxN\|YoRjJ\|NEe5NVM3RC:jPh?=
786-0	NF;qOpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXmxMVIx\|ryP	M2WxeVczcA>?	M13PR2ROW09?	NF[weIdKSzVy78{cNe69VQ>?	NHrKcYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S3PVE{Pid-MkO0O\|kyOzZ:L3G+
human HCC cell lines	NIX0Z5hE\WyuII\pZYJqdGm2eTDhd5NigQ>?	NIf5XFExNjByNT2x{txO	NGTBeHA1QGh?		NWnvN491UUN3ME2x{txO	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR6OUm5PUc,OjN2OEm5PVk9N2F-
Huh7	MnXtT4lv[XOnIFHzd4F6	M1raelHPxE1?	NETkVpQ1QGh?		MV7zbYdvce,ugXPhcpRtgSC{ZXT1Z4V{KHCqb4PwbI9zgWyjdHnvckBw\iCDa4S=	M3HxeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEi5PVk6Lz5{M{S4PVk6QTxxYU6=
human NSCLC cell lines	M1XzdGFxd3C2b4Ppd{BCe3OjeR?=	NW\x[IVrOC5zMkWtOO69VQ>?	M{D4PVI1cA>?	MWTEUXNQ	M1rNR2lEPTC\|IILhcodmeyCocn;tJFAvPC1{zszN	NHzTVZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2NlQ4Oid-MkO1OlI1PzJ:L3G+
Primary CLL cells	MWXBdI9xfG:\|aYOgRZN{[Xl?	MXWxMVEx\|ryP	MV[0PIg>		NF[1XYpqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCFTFygZ4VtdHNiaX7k[ZBmdmSnboSgc4YheHKxZ37vd5Rq[yCvYYLr[ZJ{	NGPG[4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i1NFgxPyd-MkO4OVA5ODd:L3G+
Primary CLL cells	NUDNc3p{U2mwYYPlJGF{e2G7	M3nhXlLPxE1?	M365clMxdWmw		NHr4bHZl\WO{ZXHz[YQhWEl\|SzDhZ5Rqfmm2eR?=	MnHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NUC4NFcoRjJ\|OEWwPFA4RC:jPh?=
Primary CLL cells	MVXDfZRwfG:6aXOgRZN{[Xl?	MkLWNu69VQ>?	M3nSN\|I1cA>?		NF\YZZdqdmS3Y3XzJINmdGxiY4n0c5RwgGmlaYT5	NG\DToc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i1NFgxPyd-MkO4OVA5ODd:L3G+
LC-1/SQSF	NVPxe3YzTnWwY4Tpc44hSXO\|YYm=	Mm\1N:69VQ>?	NYfCSW12OjSq	NG\TPVJFVVOR	NHuxcIJl\WO{ZXHz[UBPWkZ{IIDyc5RmcW5ibHX2[Yw>	Mo\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OECwPVMoRjJ\|OUiwNFk{RC:jPh?=
BCR-ABL	NFXNemxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX2wMlI2NTFyzszN	NY\sWXczPGR?		MnTVd4lodmmoaXPhcpRtgSCrbnjpZol1KGOnbHygdJJwdGmoZYLheIlwdg>?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NE[xNkc,OjR{NES2NVI9N2F-
T-ALL	NHyyR5lCeG:ydH;zbZMhSXO\|YYm=	M{PHOYJmfHenZX6gNU41KGGwZDC1MlMhdU1iYYSgNlRpKGGwZDCwMlkh[W6mIEWuOUBuVSCjdDC0PIghcW5iZHnm[oVz\W62IHPlcIwhdGmwZR?=	MU[yOEBweiB2OHi=	MV7EUXNQ	NIP3WXhi\m[nY4TzJJRp\SCSSUPLJJBifGi5YYmgbY4hXC2DTFygZ4VtdCCuaX7ldy=>	NVK4bIFGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNVA4OzZpPkK0N\|ExPzN4PD;hQi=>
H1975	NFPp[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjENE4{NTlwNt88US=>	NXXDdGZwPzKq	MVrEUXNQ	NXW3XZpUUUN3ME2xMlM5Pc7:TR?=	NXzVTVFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzN\|c5PDZpPkK0N\|M4QDR4PD;hQi=>
H1975	NWr0cpF{SXCxcITvd4l{KEG\|c3H5	MmTGNu69VQ>?	NWq5S5lbOjSq	NUj2NI97TE2VTx?=	NWP2T2YycW6lcnXhd4V{KGGyb4D0c5NqeyC{YYTlJJNq\26rZnnjZY51dHl?	M1ThclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{O3PFQ3Lz5{NEOzO\|g1PjxxYU6=
BON	NUjYU2N{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\1fWIyNTYQvF2=	MXG3Nog>		MXnk[YNz\WG\|ZYOgZ4VtdCCycn;sbYZmemG2aX;u	M3\LZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NESzOVI{Lz5{NES0N\|UzOzxxYU6=
BON	MUXBdI9xfG:\|aYOgRZN{[Xl?	NE\KTVQyNTYQvF2=	NHHDcFQzPGh?		NITpfmlqdmO{ZXHz[ZMh[XCxcITvd4l{	M3T1UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NESzOVI{Lz5{NES0N\|UzOzxxYU6=
GBM	NHnjUpBCeG:ydH;zbZMhSXO\|YYm=	NXjrXXJ1Os7:TR?=	NEXvUWw1QGh?	NUnINYZ4TE2VTx?=	MWfpcoR2[2WmIHjp[4hmeiCuZY\lcJMhd2ZiYYDvdJRwe2m\|LDDhcoQh\GWlcnXhd4VlKGOnbHygeoli[mmuaYT5	NWjGboY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NFA1QTJpPkK0OVAxPDl{PD;hQi=>
FaDu	MVXGeY5kfGmxbjDBd5NigQ>?	NELoXGY2KM7:TR?=	MWKyOEBp	NHPYTXdFVVOR	NFToTnNT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ\|MUG0O{c,OjR4M{GxOFc9N2F-
EMT6	M{fYT2Z2dmO2aX;uJGF{e2G7	MoDaOUDPxE1?	M3m2NlI1KGh?	MVjEUXNQ	MnLEVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36=	MnzsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{GxOFcoRjJ2NkOxNVQ4RC:jPh?=
HCT116	MWfGeY5kfGmxbjDBd5NigQ>?	NHj3dHk2KM7:TR?=	NXvaZmJoOjRiaB?=	MVrEUXNQ	MXrS[YR2[2W\|IH;4fYdmdiClb37zeY1xfGmxbh?=	MlfHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{GxOFcoRjJ2NkOxNVQ4RC:jPh?=
U87	M3z1b2Z2dmO2aX;uJGF{e2G7	MUi1JO69VQ>?	M2H1elI1KGh?	NIfsdZVFVVOR	NV;HU25zWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44>	Mn7hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{GxOFcoRjJ2NkOxNVQ4RC:jPh?=
Saos-2	MVjGeY5kfGmxbjDBd5NigQ>?	NWDRSm1lPTBizszN	NV71ToZsPDhiaB?=		NXzsdWtuUW6qaXLpeJMh[2WubDDpcpZie2mxbh?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{N{[2NEc,OjR5Mke2OlA9N2F-
MG-63	MULGeY5kfGmxbjDBd5NigQ>?	NF;xRWw2OCEQvF2=	MVW0PEBp		NYLjT5NSUW6qaXLpeJMh[2WubDDpcpZie2mxbh?=	M1HG[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO\|Y3ODxxYU6=
SJSA-1	M13wT2Z2dmO2aX;uJGF{e2G7	MmXHOVAh\|ryP	NF7Bc\|Q1QCCq		NHzpZ4tKdmirYnn0d{Bk\WyuIHnueoF{cW:w	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{N{[2NEc,OjR5Mke2OlA9N2F-
Saos-2	MYjGeY5kfGmxbjDBd5NigQ>?	MWi1NEDPxE1?	NG\UfHU1QCCq		M1:4S2lvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG\|ZT2yJIV5eHKnc4Ppc44>	NIK4UHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
MG-63	NWjBeXBGTnWwY4Tpc44hSXO\|YYm=	NETleIw2OCEQvF2=	NHq3T3A1QCCq		NVfoPWFmUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>?	NFHI[pE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
SJSA-1	M3:5UGZ2dmO2aX;uJGF{e2G7	NWLB[5lIPTBizszN	NWW2WnM6PDhiaB?=		NGjvc\|BKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v	NFvCcY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
Saos-2	NGLGcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXm1NEDPxE1?	NIX3dHE1QCCq		NXX0[4NzUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=	M2jMVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO\|Y3ODxxYU6=
MG-63	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXe1NEDPxE1?	NV3pOGQxPDhiaB?=		NILuT2FKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=	MkLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
SJSA-1	Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWm1NEDPxE1?	MX:0PEBp		MXzJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?	NYjlU3dxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3Nlc3PjBpPkK0O\|I4PjZyPD;hQi=>
LN18	Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzhN5YzOCEQvF2=	NEPoU\|g4OiCq	MXLEUXNQ	NF;FTJNKSzVyPEWg{txO	MoXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEGwO\|QoRjJ2N{SxNFc1RC:jPh?=
LN229	NGLQSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TpRlIxKM7:TR?=	NEPTemw4OiCq	NIXXfJRFVVOR	MXfJR\|UxRDVizszN	MkntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEGwO\|QoRjJ2N{SxNFc1RC:jPh?=
LNZ308	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLUNlAh\|ryP	MWq3NkBp	MV7EUXNQ	MVXJR\|UxRDVizszN	Mki3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEGwO\|QoRjJ2N{SxNFc1RC:jPh?=
T98G	NVzuNGQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHwNlAh\|ryP	NFP4PFY4OiCq	NGrPfpdFVVOR	M1HGWGlEPTB:NTFOwG0>	NIPse2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0NVA4PCd-MkS3OFExPzR:L3G+
U87	MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fKNVIxKM7:TR?=	NXvufVdSPzJiaB?=	MVrEUXNQ	NEflToNKSzVyPEWg{txO	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2MUC3OEc,OjR5NEGwO\|Q9N2F-
LN18	NHf6c3lHfW6ldHnvckBCe3OjeR?=	MnXJOUDPxE1?	MnzLNlQhcA>?	NEfD[YdFVVOR	NUPqbVY{UW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?=	M1zP[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{SxNFc1Lz5{NEe0NVA4PDxxYU6=
LNZ308	MX\GeY5kfGmxbjDBd5NigQ>?	M3\0fFUh\|ryP	M1zi[lI1KGh?	M1u1S2ROW09?	NGj3blFKdmirYnn0d{BxcG:\|cHjvdplt[XSrb36gc4YhSUuW	NV\IdJd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFExPzRpPkK0O\|QyODd2PD;hQi=>
MDA-MB-175	NEnNd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXubVJ{OSEQvF2=	NHjLbG42KGR?	Mnq1SG1UVw>?	M2\TO2lEPTB:MTFOwG0>	MkjuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
MDA-MB-134	NUn3Xm8zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\iNUDPxE1?	MmnHOUBl	M4nud2ROW09?	NEXLeHFKSzVyPEGg{txO	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
HCC1500	NIPpVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4r6[\|Eh\|ryP	NGK4OnE2KGR?	MUDEUXNQ	NG\R[WFKSzVyPEGg{txO	M{nWdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
EFM-19	MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDOeYVZOSEQvF2=	MmnBOUBl	NFn2[YdFVVOR	MknMTWM2ODxzIN88US=>	NImxblc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
ZR-75-30	M{XHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vlb\|Eh\|ryP	M{DYV\|Uh\A>?	NVrUXnE{TE2VTx?=	NHPEcZpKSzVyPEGg{txO	NH\qd4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
MDA-MB-361	M3TKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{e4bVEh\|ryP	M3LDSlUh\A>?	MUHEUXNQ	MU\JR\|UxRDFizszN	MlzTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
T-47D	NYHlUI5yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV:zPVE5OSEQvF2=	NGLPbmQ2KGR?	NET5XVlFVVOR	MoX5TWM2ODxzIN88US=>	NIrkdo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
SK-BR-3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7mNUDPxE1?	Mmi2OUBl	NIPWTlBFVVOR	NX\FNIR3UUN3MEyxJO69VQ>?	NITzdnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
UACC-732	MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPmW2o2OSEQvF2=	M1n5ZVUh\A>?	M4PHPGROW09?	MVTJR\|UxRDFizszN	MkPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
BT-474	MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrsNUDPxE1?	MWm1JIQ>	M3TC[mROW09?	MoTyTWM2ODxzIN88US=>	NVP2[4RvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC202	NF24boJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVSxJO69VQ>?	MVS1JIQ>	NVWzZ3BPTE2VTx?=	NUTZbGc1UUN3MEyxJO69VQ>?	NH:4bHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
MCF7	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVmxJO69VQ>?	MW[1JIQ>	MVrEUXNQ	NFKwbYtKSzVyPEGg{txO	NUPsN4NqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
MDA-MB-415	NGnacG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37wTVEh\|ryP	NEWzWZE2KGR?	NYG5cFZkTE2VTx?=	NEfZUZRKSzVyPEGg{txO	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
MDA-MB-453	M2\KPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjl[mgyKM7:TR?=	NVLRTIFMPSCm	NHj4UndFVVOR	NXewVVJFUUN3MEyxJO69VQ>?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
ZR-75-1	NX[2SHh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHicJoyKM7:TR?=	M3z3OFUh\A>?	MXvEUXNQ	NWHhOlJEUUN3MEyxJO69VQ>?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
HCC38	Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXOxJO69VQ>?	M2npUFUh\A>?	MX;EUXNQ	NHXRZoFKSzVyPEGg{txO	MlixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
HCC1419	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHQNUDPxE1?	NE\wTGc2KGR?	MoWzSG1UVw>?	MYfJR\|UxRDFizszN	M3;4S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
UACC-812	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{na[lEh\|ryP	M17XOFUh\A>?	M3rKVGROW09?	MnnhTWM2ODxzIN88US=>	NFe4ZlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
HCC1187	NV2ySlliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nCOFEh\|ryP	NFjFfpc2KGR?	Mm\vSG1UVw>?	NEH3TVZKSzVyPEGg{txO	M4GzSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
KPL-1	NF;2XWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVOxJO69VQ>?	M2LOT\|Uh\A>?	MUHEUXNQ	M{DITmlEPTB:MTFOwG0>	M4D6XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
SUM-225	NXXuUIh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXruVlM5OSEQvF2=	M3TiUFUh\A>?	MUjEUXNQ	NHLxSYRKSzVyPEGg{txO	M2HnO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
EFM-192A	Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPsUJEyKM7:TR?=	Mm\GOUBl	M{D2[mROW09?	MWjJR\|UxRDFizszN	M{TETlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
JIMT-1	M3j5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGP5VooyKM7:TR?=	MXy1JIQ>	M2\kXmROW09?	MXXJR\|UxRDFizszN	MojYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
HCC1143	MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXuxJO69VQ>?	M3f1[lUh\A>?	M3vpbmROW09?	MlK3TWM2ODxzIN88US=>	M2f6e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
HCC2218	M3rwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1K3eVEh\|ryP	M3Pr[\|Uh\A>?	MmLCSG1UVw>?	NHqwVmtKSzVyPEGg{txO	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
MDA-MB-468	NEjGVHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojmNUDPxE1?	NYju[\|c5PSCm	M{DpOmROW09?	M4G0T2lEPTB:MTFOwG0>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
BT-20	NV7DU\|c5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPKNUDPxE1?	MYq1JIQ>	Mo\FSG1UVw>?	MVnJR\|UxRDFizszN	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
MDA-MB-435	M2nEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3D[4t2OSEQvF2=	MVu1JIQ>	MljhSG1UVw>?	NIjJSJJKSzVyPEGg{txO	NGHJe3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
BT-549	M2D4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\pUYwyKM7:TR?=	M33nVVUh\A>?	NUHGWoRtTE2VTx?=	MULJR\|UxRDFizszN	NX32fY94RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC1806	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVOxJO69VQ>?	NUPIWnRSPSCm	NFHhTVlFVVOR	NYHD[2ZIUUN3MEyxJO69VQ>?	NGfUSWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
HCC1937	NHHS[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TFeVEh\|ryP	NIL6Z3k2KGR?	M3zhdmROW09?	M4r2UmlEPTB:MTFOwG0>	Ml6wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
Hs578T	NVyy[3ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DIRVEh\|ryP	MXK1JIQ>	NIrPNJlFVVOR	NF;VfY9KSzVyPEGg{txO	NVrjb2VORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
MCF7	MnqwR5l1d3SxeHnjJGF{e2G7		M2CzU\|czKGh?	M2TTNmROW09?	M13POmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh\XiycnXzd4lv\yCSSUPLZYxxcGFiRUW0OWshdXW2YX70JJdqfGhiR1m1NEBw\iByLkCwNFE2QCEQvF2=	NGDNfms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
DU145	MXHDfZRwfG:6aXOgRZN{[Xl?		MoXZO\|IhcA>?	MYLEUXNQ	MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BmgHC{ZYPzbY5oKEyNQkGgcZV1[W62IIfpeIghT0l3MDDv[kAxNjByMESzOUDPxE1?	NWTVSYNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
A2780	MYjDfZRwfG:6aXOgRZN{[Xl?		MV23NkBp	M4i5PGROW09?	M4f0d2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCWRV6t[IVncWOrZX70JIh2dWGwIFGyO\|gxKGOnbHzzJJdqfGhiR1m1NEBw\iByLkCwNFY{PSEQvF2=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEK2Okc,OjR7MECyOlY9N2F-
U87MG	MmTFR5l1d3SxeHnjJGF{e2G7		MVi3NkBp	NVjMS3BwTE2VTx?=	NXy1[FlJS3m2b4TvfIlkcXS7IHHnZYlve3RiUGTFUk1l\W[rY3nlcpQhcHWvYX6gWVg4VUdiY3XscJMhf2m2aDDHTVUxKG:oIECuNFAxPjl6IN88US=>	M4HZVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwNlY3Lz5{NEmwNFI3PjxxYU6=
A2780	NYL0XJBETnWwY4Tpc44hSXO\|YYm=		NYL0bGpmOSCq	M4LOVWROW09?	MkD3TY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O\|MheGixc4Doc5J6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkC1OUDPxE1?	MkKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
DU145	MYnGeY5kfGmxbjDBd5NigQ>?		NGjCe3QyKGh?	MUnEUXNQ	MVfJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gSHUyPDViY3XscJMhcGG{Yn;ybY5oKEyNQkGgcZV1[XSrb36ge4l1cCCHQ{WwJI9nKDBwMEezJO69VQ>?	NUnvW4RjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
A2780	M1rp[2Z2dmO2aX;uJGF{e2G7		NYLEUJBvOSCq	Ml\MSG1UVw>?	MUXJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:\|cHjvdplt[XSrb36gbY4hWFSHTj3k[YZq[2mnboSgbJVu[W5iQUK3PFAh[2WubIOge4l1cCCHQ{WwJI9nKDBwMEe0JO69VQ>?	NGLuXo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
MCF7	NH3VNm5HfW6ldHnvckBCe3OjeR?=		NXm2eXJHOSCq	MnT5SG1UVw>?	M2eyfmlvcGmkaYTpc44hd2ZiUFmzT4FteGijIFW1OFVMKG23dHHueE1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6xJO69VQ>?	NYfaTJBzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
U87MG	MVjGeY5kfGmxbjDBd5NigQ>?		Mmq4NUBp	MnPPSG1UVw>?	M2\0cGlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFXDOVAhd2ZiMD6xN{DPxE1?	NIHaSow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
A2780	Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnHVO\|IhcA>?	MYDEUXNQ	NHL3R5NGSzVyPUCuOVIh\|ryP	NVnDNYJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
Huh7	MYPGeY5kfGmxbjDBd5NigQ>?	MWixJO69VQ>?	NXH2VVhHOSCq	MWHEUXNQ	Mkn1TY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDT[ZI1PzR?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByNESwN{c,OjVyMES0NFM9N2F-
BNL	MVLGeY5kfGmxbjDBd5NigQ>?	NVLjW2JIOSEQvF2=	NFrze2EyKGh?	M1m1V2ROW09?	NEDxNmVKdmirYnn0d{BxcG:\|cHjvdplt[XSrb36gc4YhWzZ?	MkLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMES0NFMoRjJ3MEC0OFA{RC:jPh?=
BON-1	MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWW1NFAhdk1?	M{LEV\|ExKGR?	MX7EUXNQ	MUnJcohq[mm2czDj[YxtKGe{b4f0bC=>	NXHVN4hiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlYzQTJpPkK1NFI3Ojl{PD;hQi=>
BON-1	MnjFSpVv[3Srb36gRZN{[Xl?	NVPtUmNtPTByIH7N	MVO0JIg>	Mk[xSG1UVw>?	MkjsTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?=	MnfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMk[yPVIoRjJ3MEK2NlkzRC:jPh?=
QGP-1	MnTHSpVv[3Srb36gRZN{[Xl?	MXu1NFAhdk1?	MnXpOEBp	NV\WeGNoTE2VTx?=	NH3PS3RKdmirYnn0d{BxcG:\|cHjvdplt[XSrb36gc4YhSUuWIHH0JHRpejNyODDhcoQhW2W{NEez	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB{NkK5Nkc,OjVyMk[yPVI9N2F-
HCT-15	MnO2RZBwfG:\|aYOgRZN{[Xl?	MXqxNEDPxE1?	NV:5Z20xPDhiaB?=	MmP0SG1UVw>?	M2DwVWlv\HWlZYOgZZBweHSxc3nzJIlvKEiFVD2xOUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w	NILxOpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NlI1PSd-MkWxOVIzPDV:L3G+
HCT-116	MYrBdI91d3OrczDBd5NigQ>?	NYjYR2FkOTBizszN	NUTQbYxQPDhiaB?=	MYHEUXNQ	MlS1TY5lfWOnczDhdI9xfG:\|aYOgbY4hUEOWLUGxOkBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w	M{LpNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
NCI-H460	NUHQT2xxSXCxdH;zbZMhSXO\|YYm=	NF7N[FYyOCEQvF2=	M2TIcFQ5KGh?	NYrSVJB7TE2VTx?=	MlzHTY5lfWOnczDhdI9xfG:\|aYOgbY4hVkOLLVi0OlAh[2WubIOgbIFz[m:3cnnu[{BRUUt\|Q1GgbI91e3CxdDDteZRifGmxbh?=	M2WzdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
SKOV-3	M4SxfGFxd3Sxc3nzJGF{e2G7	NVzKd5dMOTBizszN	NUfEfHMyPDhiaB?=	MV3EUXNQ	NUHhO5FSUW6mdXPld{BieG:ydH;zbZMhcW5iU1vPWk0{KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36=	MlnjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
BSY-1	MV;BdI91d3OrczDBd5NigQ>?	NYq2RYJyOTBizszN	MX:0PEBp	M{TjdGROW09?	MYXJcoR2[2W\|IHHwc5B1d3OrczDpckBDW1lvMTDj[YxteyCqYYLic5VzcW6pIGDJT\|NESSCqb4TzdI91KG23dHH0bY9v	NUjuN4d[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
MKN-1	NVzNe21qSXCxdH;zbZMhSXO\|YYm=	NIDWT5gyOCEQvF2=	M3vvcVQ5KGh?	NWfLUGxTTE2VTx?=	NXXpc4dRUW6mdXPld{BieG:ydH;zbZMhcW5iTVvOMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt\|Q1GgbI91e3CxdDDteZRifGmxbh?=	NH;qO4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NlI1PSd-MkWxOVIzPDV:L3G+
NCI-H522	NIKzSFdCeG:2b4Ppd{BCe3OjeR?=	NELOc2cyOCEQvF2=	NXnkWoRXPDhiaB?=	NV\5O2ZDTE2VTx?=	MoPkTY5lfWOnczDhdI9xfG:\|aYO=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
OVCAR-3	NXrPV3BkSXCxdH;zbZMhSXO\|YYm=	M4fuZ\|ExKM7:TR?=	Mn3JOFghcA>?	M{\DPWROW09?	NVTNO3dTUW6mdXPld{BieG:ydH;zbZM>	MkDmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
HBC-5	NFy0[25CeG:2b4Ppd{BCe3OjeR?=	MmL2NVAh\|ryP	M1yyPVQ5KGh?	NHu3OI5FVVOR	M4G1fmlv\HWlZYOgZZBweHSxc3nz	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
RXF-631L	MlXHRZBwfG:\|aYOgRZN{[Xl?	M1jZT\|ExKM7:TR?=	MmXHOFghcA>?	NWrmcmZ4TE2VTx?=	M1Hpb2lv\HWlZYOgZZBweHSxc3nz	NXHPZ\|lFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
MKN-45	MmHCRZBwfG:\|aYOgRZN{[Xl?	M1zhT\|ExKM7:TR?=	NXvhU2hnPDhiaB?=	MUPEUXNQ	MoryTY5lfWOnczDhdI9xfG:\|aYO=	NXTZNYd1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
LNCaP	MnL0SpVv[3Srb36gRZN{[Xl?	M3HKU\|Eh\|ryP			NFvkWpdUfXCycnXzd4V{KHBvQVvUJIxmfmWucx?=	NGHnT2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO2NFc6QSd-MkWzOlA4QTl:L3G+
LNCaP95	NE\kNmRHfW6ldHnvckBCe3OjeR?=	NGfBTnYyKM7:TR?=			NXHtfmtvW3WycILld5NmeyCyLVHLWEBt\X[nbIO=	NYLXb5NvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzOlA4QTlpPkK1N\|YxPzl7PD;hQi=>
A549	NIDCdpBHfW6ldHnvckBCe3OjeR?=	NIjVU5E2ODBibl2=	NGm5eZQ1QCCq	NXfJUmtmTE2VTx?=	M1jjZWlvcGmkaYTzJGFsfCCjY4TpeoF1cW:w	Moq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7M{eyPVkoRjJ3OUO3Nlk6RC:jPh?=
A549	NVvGR2FST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEC1V\|AyKM7:TR?=	M{PRO\|czKGh?	MYfEUXNQ	M{PLV2lvcGmkaYTzJINmdGxiZ4Lve5Rp	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl\|N{K5PUc,OjV7M{eyPVk9N2F-
H522	NX7ZS21uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TGWlEh\|ryP	MXm3NkBp	M{LjbGROW09?	NVvFWJRGUW6qaXLpeJMh[2WubDDndo94fGh?	NYHRXmZ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5N\|czQTlpPkK1PVM4Ojl7PD;hQi=>
SKMES-1	NH;FUpREgXSxdH;4bYMhSXO\|YYm=	NV;6PJZbOSEQvF2=	Mnq4O\|IhcA>?		MofsTY5lfWOnczDj[YxtKGSnYYTo	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjBzM{OxPEc,OjZyMUOzNVg9N2F-
H596	NY\zU2VNTnWwY4Tpc44hSXO\|YYm=	NULocoxQOSEQvF2=			NYPmdZpEUW2yYXnyd{Bk\WyuIH3p[5JifGmxbh?=	NHjGXpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCxN\|MyQCd-Mk[wNVM{OTh:L3G+
HCC2450	NEnsdoZHfW6ldHnvckBCe3OjeR?=	NFTKbIQyKM7:TR?=			NUXUW4s3UW2yYXnyd{Bk\WyuIHnueoF{cW:w	M{LNZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEGzN\|E5Lz5{NkCxN\|MyQDxxYU6=
HCT116	NHjJ[49CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NFTtRYo4OiCqcoO=		M4P2PGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlQ5KM7:TT6=	MlHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkW5NFkoRjJ3N{[1PVA6RC:jPh?=
MCF7	M1\0RmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NVKweHpZPzJiaILz		NU[5VHJ5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxJO69VS5?	NETnVI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2OVkxQSd-MkW3OlU6ODl:L3G+
U87MG	M4XRWmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NWHG[Yd1PzJiaILz		NXK1VYtmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNU43PCEQvF2u	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4NUmwPUc,OjV5NkW5NFk9N2F-
A549	NUHSPYR[SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MYW3NkBpenN?		M4r4fmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMj6wO{DPxE1w	Mkj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkW5NFkoRjJ3N{[1PVA6RC:jPh?=
HeLa	NFL6N49CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M2nt[lczKGi{cx?=		MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEinTHGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDRwM{Sg{txONg>?	NU\1R453RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlU6ODlpPkK1O\|Y2QTB7PD;hQi=>
HCT116	NGHPPYpHfW6ldHnvckBie3OjeR?=	M1zFc\|ExKHWP	MWCxJIhz		M1fmTmlvcGmkaYTpc44hd2ZiUFmzT{9Cc3RiaX6gbJVu[W5iSFPUNVE3KGOnbHzzJIF{e2W\|c3XkJIF{KEGtdDDwbI9{eGixconsZZRqd25iYYSgNVAhfU1iYX\0[ZIhOSCqcjDifUBY\XO2ZYLuJIJtd3S2aX7nJIFv[Wy7c3nz	NH;NZ2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2OVkxQSd-MkW3OlU6ODl:L3G+
A2058 melanoma	NV3EdXRXS2WubDDjfYNt\SCjc4PhfS=>	NEKwUY42KHWP	NYTTTVNVOjRiaILz		NGP4[ZlE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBCOjB3ODDt[Yxidm:vYTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiU4XiS\|EheGijc3WgZZQhPSC3TTDh[pRmeiB{NDDodpMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\yCkYYPl[EBHSUOVIHHuZYx6e2m\|	MkDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6Mkm1PVIoRjJ6OEK5OVkzRC:jPh?=
A2058 melanoma	M17KfGNmdGxiY4njcIUh[XO\|YYm=	M1ThN\|UhfU1?	MVOyOEBpenN?		M4DKcmNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGEzODV6IH3lcIFvd22jIHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnIHH0JFUhfU1iYX\0[ZIhOjRiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG\|ZXSgSmFEWyCjbnHsfZNqew>?	M1PXWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEK5OVkzLz5{OEiyPVU6OjxxYU6=
SKOV3	NF71RVdE\WyuIHP5Z4xmKGG\|c3H5	MX6yJJVO	M1HVNVI1KGi{cx?=		M4TwTmNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJHNMV1Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnIHH0JFIhfU1iYX\0[ZIhOjRiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG\|ZXSgSmFEWyCjbnHsfZNqew>?	NGqwWJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEiyPVU6Oid-Mki4Nlk2QTJ:L3G+
SKOV3	M3[1VmNmdGxiY4njcIUh[XO\|YYm=	NULOXGRMOiC3TR?=	NGHINJkzPCCqcoO=		Mn\TR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gV2tQXjNiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KFO3YlexJJBp[XOnIHH0JFIhfU1iYX\0[ZIhOjRiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG\|ZXSgSmFEWyCjbnHsfZNqew>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh{OUW5Nkc,Ojh6Mkm1PVI9N2F-
MDA-MB-231	MYXDfZRwfG:6aXPpeJkh[XO\|YYm=		NW\mOGdmPzJiaILz		MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzLki4JO69VS5?	NY\jSGVORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxNFc1OjlpPkK5NVA4PDJ7PD;hQi=>
PC3	MWXDfZRwfG:6aXPpeJkh[XO\|YYm=		Ml\nO\|IhcHK\|		MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEWuN\|Qh\|ryPLh?=	MmDqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzMEe0NlkoRjJ7MUC3OFI6RC:jPh?=
T47D	NVLJNItlS3m2b4TvfIlkcXS7IHHzd4F6		NX;2ZndQPzJiaILz		NUnseoNRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXDR5RDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hPi57MjFOwG0v	M1j2OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUC3OFI6Lz5{OUGwO\|QzQTxxYU6=
MCF7	NFfaOGZEgXSxdH;4bYNqfHliYYPzZZk>		NYrnSWU6PzJiaILz		MlzBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNVEvODVizszNMi=>	MlXLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzMEe0NlkoRjJ7MUC3OFI6RC:jPh?=
TC32	Mn6xdWhVWyCjc4PhfS=>				NYXYOXJLeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGTDN\|Ih[2WubIO=	MmfRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	MUDxTHRUKGG\|c3H5				MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	NHjVT4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	NYTldmJEeUiWUzDhd5NigQ>?				Mn[wdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	NH3HPHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	NILt[INyUFSVIHHzd4F6				MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	NYToS2lyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	NX3QUG5EeUiWUzDhd5NigQ>?				NF\aPWFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN\|ch[2WubIO=	NH\OSmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	NWjNXWRqeUiWUzDhd5NigQ>?				NXLKWZhEeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	MWjxTHRUKGG\|c3H5				MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-12	MnLNdWhVWyCjc4PhfS=>				MkDFdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|	NXHEWJd4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	NUfhNpdSeUiWUzDhd5NigQ>?				NWLpXJZXeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	NYjUXmFjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	M1PwNpFJXFNiYYPzZZk>				NGLNPXFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	Mk\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	NEHoT\|hyUFSVIHHzd4F6				Mnn3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	MnrnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	NUXROG54eUiWUzDhd5NigQ>?				M32w[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN?	M1GyRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	MojIdWhVWyCjc4PhfS=>				Mo\QdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	M1rBR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	MmDjdWhVWyCjc4PhfS=>				NFrYTnVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd\|IHPlcIx{MQ>?	NF:0UFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh30	NVy4cYdKeUiWUzDhd5NigQ>?				M2TaWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy\|	NU[2OnNxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	M2jNXpFJXFNiYYPzZZk>				M2DuOpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG1IKDZ\|IDi2MXRIKFJrIHPlcIx{	NWPlWnFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30	MXzxTHRUKGG\|c3H5				NIT0VWJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDNyIHPlcIx{	M1XQZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS	NI\OO3pyUFSVIHHzd4F6				MnvhdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWU0zKE:VIHPlcIx{	M{DhWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	M37EZpFJXFNiYYPzZZk>				NHfRNGJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	MoX0dWhVWyCjc4PhfS=>				Mni5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVmQh[2WubIO=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	NEXuOGZyUFSVIHHzd4F6				NYXTTY55eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NEnm[FByUFSVIHHzd4F6				MkX1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MoHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	M{jicJFJXFNiYYPzZZk>				NWXwO\|lSeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	NWLQUpZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	MkTBdWhVWyCjc4PhfS=>				Mm[wdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	NV;wbYx5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	M2jtd5FJXFNiYYPzZZk>				MlvvdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	MXnxTHRUKGG\|c3H5				M1TXR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN?	NUTHW2ZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	MV\xTHRUKGG\|c3H5				MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
insect	NG\pbXlHfW6ldHnvckBie3OjeR?=				M3vtPGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iSHnzMZRi\2enZDDwPFVidHCqYT;wNVEx[WyyaHGgSVU1PUtibYX0ZY51KGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMtKEmFNUCgQUAxNjBzMTFOwG0v	NEHqeok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECzOFYxPyd-M{CwN\|Q3ODd:L3G+
insect	NEO5XJBHfW6ldHnvckBie3OjeR?=				M{DSe2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iSHnzMZRi\2enZDDwPFVidHCqYT;wNVEx[WyyaHGgSVU1OktibYX0ZY51KGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMtKEmFNUCgQUAxNjB{OTFOwG0v	M2jVSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEO0OlA4Lz5\|MECzOFYxPzxxYU6=
Sf21	NV31d4VUTnWwY4Tpc44h[XO\|YYm=		NFToU3oyKGi{		MljETY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsMYxmdme2aDDOMZRmem2rbnHsJGhqezZvdHHn[4VlKHBzMUDk[Yx1[S:{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDwPFVidHCqYTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[yNUBqdnOnY4SgZ4VtdHNidYPpcochWEmSMjDhd{B{fWK\|dILheIUhdWWjc4Xy[YQh[W[2ZYKgNUBpeiCkeTDBcIV5[TZ\|MzDUdoFk\XJvYnHz[YQh\my3b4Lld4NmdmOnIIDvcIFzNCCLQ{WwJF0hOC5zMkWg{txONg>?	M1y0UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEO0OlA4Lz5\|MECzOFYxPzxxYU6=
MCF7	MnToRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUK3NkBpenN?		NVfQXmg4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIhiemKxcnnu[{BRUUt\|Q1GgSVU1PUtibYX0ZY51KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjJyNjFOwG0v	NXzRV5lCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|Q3ODdpPkOwNFM1PjB5PD;hQi=>
Sf21	MX7GeY5kfGmxbjDhd5NigQ>?		MX:xJIhz		MnnoTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsMYxmdme2aDDOMZRmem2rbnHsJGhqezZvdHHn[4VlKHBzMUDi[ZRiN3KnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIIC4OYFteGijIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkKxJIlve2WldDDj[YxteyC3c3nu[{BRUVB{IHHzJJN2[nO2cnH0[UBu\WG\|dYLl[EBi\nSncjCxJIhzKGK7IFHs[ZhiPjN\|IGTyZYNmei2kYYPl[EBndHWxcnXzZ4Vv[2VicH;sZZJqNCCLQ{WwJF0hOC5{M{Sg{txONg>?	NV;lO5E{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|Q3ODdpPkOwNFM1PjB5PD;hQi=>
T47D	MmPFRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NHfiVYo4OiCqcoO=		MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFR2N1SgZ4VtdHNiaHHyZo9zcW6pIGDJN2tESSCKMUC0O3IhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlI5PiEQvF2u	Mo\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{S2NFcoRjNyMEO0OlA4RC:jPh?=
PC3	MoTkSpVv[3Srb36gZZN{[Xl?		Mk\wNkBpenN?		M1nBZ2lvcGmkaYTpc44hd2ZiUFmzT{BqdiCqdX3hckBRSzNiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGFMXCCyaH;zdIhwenmuYYTpc44h[XRiU3XyOFc{KG2nYYP1doVlKGGodHXyJFIhcHK\|IHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvOzZ3IN88UU4>	NV3UWXBYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|Q3ODdpPkOwNFM1PjB5PD;hQi=>
HT-29	NH\Dd25E\WyuIHP5Z4xmKGG\|c3H5	NGi1cocxNjFzMTD0c{A{KHWP	MWWyOEBpenN?		MVnD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzJxTTDwbIF{\SCjdDCwMlEyOSC2bzCzJJVOKGGodHXyJFI1KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJie2WmIH\sc5ch[3m2b33leJJ6	NI\PbJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECzOFYxPyd-M{CwN\|Q3ODd:L3G+
A2058	MnT2SpVv[3Srb36gZZN{[Xl?		NXzkfGt2OSCqch?=		NX7iTGxHUW6qaXLpeIlwdiCxZjDUU3JEOiCrbjDoeY1idiCDMkC1PEBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCSS1KvRYt1KHCqb4PwbI9zgWyjdHnvckBifCCVZYK0O\|Mh[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZMtKEmFNUCgQUAxNjRzNjFOwG0v	M2q1SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{W5NFA{Lz5\|MEO1PVAxOzxxYU6=
A2058	NWTVeot6TnWwY4Tpc44h[XO\|YYm=		M2TPe\|EhcHJ?		MVPJcohq[mm2aX;uJI9nKFSRUlOxJIlvKGi3bXHuJGEzODV6IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJHM3KHCqb4PwbI9zgWyjdHnvckBifCCVZYKyN\|UwOjN4IHHmeIVzKDFiaIKgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|LDDJR\|UxKD1iMD61OVMh\|ryPLh?=	Mk\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NUmwNFMoRjNyM{W5NFA{RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT (T308) / p-AKT (S473) / AKT; PubMed: 27283525 J Neurooncol Left western blots showing levels of pAkt (T308), pAkt (S473) and total Akt in U87 cells exposed to buparlisib for 72 h. Right densitometric assessment of western blots, showing relative changes in phosphorylation. p-FOXO3a (S253) / FOXO3a; PubMed: 28036259 Oncotarget Cells were treated with 0.5 μM BKM120 for 24 h and cell lysates were immunoblotted with the indicated antibodies. Actin was used as the loading control. Nuclear NF-κB p65 / NF-κB p65; PubMed: 26673665 Cell Death Dis Western blots show BKM120 downregulating pAKT, nuclear NF-κB p65 and total NF-κB p65 in MDR and their parental cells. β-actin was used as a loading control for pAKT, AKT and total NF-κB p65. Lamin B was used as a loading control for nuclear NF-κB p65. p-ERK / ERK / LC3; PubMed: 27572309 Oncotarget The indicated cell lines were exposed to different concentrations of BKM120 as indicated for 8 h A. or with 2 μM BKM120 for the indicated times B. The cells were then harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis to detect the given proteins. p-STAT3 / STAT3 / p-ERK / ERK / p-S6; PubMed: 29928341 Oncol Lett Western blot analysis of H460 and H2126 cell lysates using specific antibodies to phosphorylated or total proteins of STAT3, ERK1/2, AKT, S6 or GAPDH (loading control). The cells were treated with increasing concentrations of BKM120 for 24 h. p-MET / MET; PubMed: 29928341 Oncol Lett The expression of phosphorylated or total forms of MET protein was analyzed by western blotting.	27283525 28036259 26673665 27572309 29928341
Immunofluorescence	FOXO3a; PubMed: 28036259 Oncotarget Cells were cultured on coverslips to approximately 60% confluency and then treated with 1 μM BKM120 for an additional 24 h. Immunofluorescence staining was performed using an anti-FOXO3a antibody and the nuclei were stained with DAPI. Scale bar, 20 μm.	28036259
Growth inhibition assay	Cell viability; PubMed: 26673665 Cell Death Dis Dose-response curves were used to calculate the IC50 of BKM120 for MCs of MCF-7/A02 cells (upper) and CALDOX cells (lower).	26673665

In vivo

BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. ^[1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse PI3K biochemical assay (ATP depletion assay): BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl₂, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
Cell Research:^[1]	- Collapse Cell lines: A2780 cells. Concentrations: 0-6.6 μM Incubation Time: 3 days. Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 10³ cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice. Dosages: ~60 mg/kg. Administration: Dosed orally daily (q.d.). (Only for Reference)

References

[4] Koul D, et al. Clin Cancer Res, 2012, 18(1), 184-195.

- Collapse

Solubility (25°C)

In vitro	DMSO	82 mg/mL (199.8 mM)
	Ethanol	2 mg/mL (4.87 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Buparlisib (BKM120) SDF

Molecular Weight	410.39
Formula	C₁₈H₂₁F₃N₆O₂
CAS No.	944396-07-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NVP-BKM120
Smiles	C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04338399	Not yet recruiting	Drug: Buparlisib & Paclitaxel	Head and Neck Cancer	Adlai Nortye Biopharma Co. Ltd.	July 31 2020	Phase 3
NCT02614508	Terminated	Drug: Buparlisib\|Drug: Ibrutinib\|Biological: Ofatumumab	Recurrent Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Small Lymphocytic Lymphoma	Emory University\|Novartis	January 2016	Phase 1
NCT01613677	Withdrawn	Drug: BKM120	Treatment for Metastatic or Locally Advanced Cervical Cancer	Novartis Pharmaceuticals\|Novartis	November 2015	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

BEZ235 (NVP-BEZ235, Dactolisib) : p110α/γ/δ/β, IC50=4 nM/5 nM/7 nM/75 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

VS-5584 (SB2343) ^New : Potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin

Wortmannin (KY 12420) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Buparlisib (BKM120)